Scope Health Inc. announced an acquisition for ‘Eye-care professionals’

Date: 29th May 2025

Scope Health Inc., a leading eye-care company, announced its acquisition to support eye-care professionals. The acquisition is a valuable collaboration with the eye-care professionals is developing the finest ecosystem of products and leveraging service performance to enhance patient care.

Announcement

The company has introduced two innovative technologies to enhance and improve the facilities. The Optase MX2 is a low-cost, cloud-based meibographer, and Optase Connect is introduced by Medbot technology. These are the solutions that can be approached by an ophthalmologist. It will increase patient engagement and use digital connectivity tools. This will elevate eyecare practices. Half of the American population is around 150 million people, detects with the symptoms of dry eye. Though most of the individuals don’t get diagnosed because of no visual symptoms. According to a scientific study traditional symptoms list is short, and goes through slit-lamp examinations. Due to which there’s no quick signal of gland dropout.

Changes

The solution has been initiated to work on this scientific study. The ‘Optase MX2’ is discovered as a box medical solution by Dr. Tim Trinh and Andy Aoe, enabling high-quality imaging. The high-quality imaging of the anterior segment and meibomian glands enhances the report service. The Optase MX2 is easy to use and portable device, mainly used as a handheld screener and also to various slit lamp platform. It’s a convenient device that contributes largely to product sales and dry eye treatments. The solution is a relief for eye-care professionals to treat and detect eye conditions. Further, the Scope Health is planning to accelerate Optase MX2 to help monitor disease progression visually, educate patients, and provide accessibility to imaging.

The Optase MX2 and Optase Connect will be available with detailed information on the eye care professional page on Optase.com.